European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. (Q33195217)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. |
scientific article |
Statements
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme (English)
W Grisold
D Frappaz
R Stupp
J P Desir
T Lesimple
C Dittrich
M J A de Jonge
M Frenay
A F Carpentier
P Chollet
J Oliveira
B Baron
D Lacombe
M Schuessler
P Fumoleau
European Organization for Research and Treatment of Cancer New Drug Development Group
European Organization for Research and Treatment of Cancer Brain Tumor Group
1 December 2003